Darvadstrocel showed no better results than placebo for Crohn's disease fistulas

People with Crohn's disease often face painful fistulas that do not heal with standard drugs. This large study tested darvadstrocel, a stem cell product, against a placebo to see if it could help close these openings. The trial involved 568 adults across Europe, Israel, and North America who had complex fistulas and had not responded to other treatments. The main goal was to see if the stem cell treatment led to better healing at 24 weeks. The results showed that 48.8% of patients in the darvadstrocel group achieved closure compared to 46.3% in the placebo group. This small difference was not statistically significant. In plain terms, the treatment did not work better than the inactive substance used for comparison. Neither group saw a meaningful improvement in how quickly healing occurred. Safety was also monitored closely. Side effects were rare and happened at similar rates for both groups. No new safety concerns were found. The study was well designed with strict controls. Yet the outcome suggests this specific stem cell therapy does not offer a clear advantage over doing nothing for this condition. Patients and doctors should weigh this neutral result carefully before considering this option.